Molecular Determinants of Atherosclerotic Cardiovascular Disease in Multi-ethnic Populations
- Institution
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX
- Principal investigator
- Bing Yu
- Funding
- $708K
- Duration
- 2023–2027
Moonbase score
Still being scored
Abstract
ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death worldwide. Understanding the process of atherosclerosis and its progression is essential to decrease ASCVD burden. Despite successful identification of genetic variants and clinical risk factors related to ASCVD over the last decade, the underlying mechanism - how genetic variants and human metabolism contribute to atherosclerosis remains unclear. Circulating metabolites, the ultimate products of gene and environment interaction, holds promise to link genetic variants, circulating metabolites to atherosclerosis. We previous work has shown that circulating metabolites involved in lipids and oxidation metabolism and their genetic determinants predict the onset of ASCVD. Few studies have examined the metabolic influence on atherosclerosis in multi-ethnic populations, and the effect of longitudinal metabolomic changes on atherosclerosis. Our overall objective is to identify circulating metabolite and its longitudinal change, along with the genetic determinants, contributing to atherosclerosis and ASCVD in middle and late life among multi-ethnic populations. We propose to conduct this project in six studies from the Trans-Omics for Precision Medicine (TOPMed) Program, including European, African and Hispanic Americans. We will leverage the unique resources from each study on whole genome sequencing (WGS) data, metabolome profiles, and atherosclerotic traits, and use TOPMed Cloud Computing as the computational engine. Our aims are: (1) to identify circulating metabolite and it change associated with ASCVD risk; (2) to determine circulating metabolite and it change associated subclinical atherosclerosis and its progression; and (3) to characterize genetic architecture of ASCVD metabolites and evaluate its association with ASCVD risk. Our team is uniquely positioned, given our expertise in ASCVD pathophysiology, metabolome profiling, genomics, biostatistics and bioinformatics. The results of this research will enable continued scientific progress toward an understanding of ASCVD etiology, with direct implications for prevention and potential therapies.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Marquette University41
Deep learning enabled, deep ultraviolet scanning microscopy for intraoperative assessment of margin status during breast cancer surgery
Dong Hye Ye · $362K · 2022–2026
- NIH · University of Texas Hlth Sci Ctr HoustonNot yet scored
Proteomic profiling of heart failure in Hispanics/Latinos
Bing Yu · $816K · 2025–2029
- NIH · University of Texas Hlth Sci Ctr HoustonNot yet scored
Genetic Architecture of Cardiac Structure and Function and Its Impact on Heart Failure
Vasan Ramachandran · $702K · 2022–2026